Evaluation of the Effects of Sodium–glucose Co‐transporter 2 Inhibition With Empagliflozin on Morbidity and Mortality in Patients With Chronic Heart Failure and a Preserved Ejection Fraction: Rationale for and Design of the EMPEROR‐Preserved Trial
European Journal of Heart Failure - United States
doi 10.1002/ejhf.1596
Full Text
Open PDFAbstract
Available in full text
Date
September 16, 2019
Authors
Publisher
Wiley